Form 4: RA Capital Boosts Stake in Bicara Therapeutics

RA Capital Management and its affiliated funds increased their beneficial ownership in Bicara Therapeutics Inc. through recent purchases of common stock and pre-funded warrants.

Summary

• RA Capital Management, L.P. and its affiliated funds acquired additional securities in Bicara Therapeutics Inc. on February 26, 2026.
• 300,000 shares of Common Stock were acquired at a price of $16 per share.
• 2,200,000 Pre-Funded Warrants were acquired at a price of $15.9999 per warrant, with an exercise price of $0.0001.
• Following these transactions, RA Capital Healthcare Fund, L.P. beneficially owns 4,603,418 shares of Common Stock and 2,200,000 Pre-Funded Warrants.
• RA Capital Nexus Fund III, L.P. beneficially owns 2,652,575 shares of Common Stock.
• The Pre-Funded Warrants have no expiration date and are exercisable at any time, subject to a 9.99% beneficial ownership cap.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive signal, indicating high conviction from a sophisticated institutional investor and existing insider.

Positives

• Significant investment by a major institutional investor and existing 10% owner, RA Capital Management, L.P., signals strong confidence in Bicara Therapeutics Inc.
• The acquisition of both common stock and pre-funded warrants demonstrates a multi-faceted commitment to the company's future.

Negatives

• NA

Risks

• NA

Future Outlook

NA

Management Comments

• RA Capital Management, L.P. (the 'Adviser') is the investment manager for RA Capital Healthcare Fund, L.P. (the 'Fund') and RA Capital Nexus Fund III, L.P. (the 'Nexus Fund III').
• The general partner of the Adviser is RA Capital Management GP, LLC (the 'Adviser GP'), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members.
• Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
• Jake Simson, a Partner of the Adviser, serves on the Issuer's board of directors.

Industry Context

StockSavvy.ai notes that significant insider buying by a prominent biotech investor like RA Capital often signals positive internal developments or strong belief in a company's pipeline, potentially attracting further investor interest in the biotechnology sector.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• RA Capital Management, L.P., an existing 10% owner and entity with directors on Bicara Therapeutics Inc.'s board, acquired additional securities.
• The transaction involves affiliated funds (RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund III, L.P.) managed by RA Capital Management, L.P.

Stakeholder Impact

• Shareholders: Existing shareholders may view this as a positive signal of confidence from a major investor, potentially leading to increased share price.
• Company: The increased stake by a significant investor could provide stability and strategic support.

Next Steps

• NA

Key Dates

Recommendation

The substantial acquisition of common stock and pre-funded warrants by RA Capital Management, a sophisticated institutional investor and existing 10% owner with board representation, signals high conviction in Bicara Therapeutics Inc.'s future. This insider buying activity, especially at a significant scale, typically precedes positive developments or reflects a strong belief in the company's underlying value, making it a compelling "strong buy" signal for seasoned investors.

Keywords

Bicara Therapeutics, BCAX, RA Capital Management, insider buying, beneficial ownership, common stock, pre-funded warrants, SEC Form 4